Transcatheter aortic valve replacement (TAVR) annual report 2023
- VernacularTitle:经导管主动脉瓣置换术2023年度报告
- Author:
Wenzhi PAN
1
;
Yanxing FANG
1
;
Jie LI
2
;
Fei LI
3
;
Daxin ZHOU
1
;
Junbo GE
1
Author Information
1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, 200032, P. R. China
2. Department of Cardiology, Guangdong Provincial People s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, P. R. China
3. Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi an, 710032, P. R. China
- Publication Type:Journal Article
- Keywords:
Transcatheter aortic valve replacement;
progress;
annual report
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(04):498-503
- CountryChina
- Language:Chinese
-
Abstract:
Transcatheter aortic valve replacement (TAVR) has seen a surge in clinical research, basic research, and innovative device development both domestically and internationally in the previous 2023. This article aims to review the progress of TAVR in the past year from the perspectives of international, and domestic research development of application. It highlights new clinical and basic research findings both domestically and internationally, the emergence of new devices and technologies, and the development and use of TAVR in China. Finally, it provides an outlook on the trajectory of TAVR development in 2024.
